Bicycle Therapeutics plc

NASDAQ:BCYC

Biotechnology

Healthcare
$3.11 -1.36%

-$0.06 today

Market cap
$217.99M
Beta
1.54
P/E (TTM)
-1.3
EPS (TTM)
-$3.14
52W Low $3.95High $9.18

Volume 0.57M

Average 0.49M

BCYC Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Bicycle Therapeutics plcNASDAQ: BCYC

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $48.9M fell 17.2% year over year, behind the +16.7% change in trailing-twelve-month research & development. Sequentially, it fell 5.5% from the prior quarter. Over 3 fiscal years it compounded at +43.3% a year.

Context

  • Research & development amounted to 331.0% of revenue in FY2025, down 159.3 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -17.2% toward the trailing-twelve-month pace of +16.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$48.9M-5.5% QoQ
Last fiscal yearDec 2025
$240.28M+38.9% YoY
LTMMar 2026
$230.13M+16.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.2%——
1 year+38.9%——
3-year CAGR+43.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
240.28M USD
Year-over-year change
+38.9%
4-year CAGR
+52.1%

Research & Development vs competitors

How BCYC compares with its peers on the latest reported figures

  • BCYC's LTM Mar 2026 research & development of $230.13M is the highest of the 10 companies compared; the peer median is $70.57M.
  • Its year-over-year change of +16.7% is the 3rd highest of 9, against a peer median of -18.7%.
  • Research & development amounts to 362.4% of revenue for BCYC, versus a peer median of 143.4%.
BCYC Competitors Peer median
Research & Development for BCYC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCYCBicycle Therapeutics plcLTM Mar 2026$230.13M +16.7%+43.3%362.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$219.98M +42.7%+34.6%249.3%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$162.51M -21.6%+18.9%—
PRTAProthena Corporation plcLTM Mar 2026$96.67M -53.8%-0.2%166.8%
ADCTADC Therapeutics S.A.LTM Mar 2026$94.95M -15.8%-17.7%119.9%
OMEROmeros CorporationLTM Mar 2026$70.57M -39.3%-10.3%713.3%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$58.28M -31.8%+5.0%83.7%
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$56.78M +0.2%-9.9%—
CMPXCompass Therapeutics, Inc.LTM Mar 2026$56.29M +22.7%+23.1%—
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$48.42M ——41.8%
Peer median (excluding BCYC) $70.57M-18.7%+2.4%143.4%

Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue11.7M14.46M26.98M35.28M72.59M
Cost of Revenue00156.5M172.97M0
Gross Profit11.7M14.46M(129.52M)(137.69M)72.59M
Gross Margin100.0%100.0%-480.1%-390.3%100.0%
Research & Development44.88M81.61M156.5M172.97M240.28M
Selling, General & Admin32.44M49.51M59.83M71.46M80.02M
Operating Expenses77.32M131.12M60.43M72.18M320.3M
Depreciation & Amortization1.41M3.69M6.55M7.18M6.42M
EBITDA(64.09M)(107.21M)(169.4M)(164.89M)(212.18M)
EBITDA Margin-547.9%-741.3%-628.0%-467.4%-292.3%
Operating Income(65.62M)(116.65M)(189.95M)(209.87M)(247.72M)
Operating Margin-561.0%-806.6%-704.1%-595.0%-341.3%
Interest Income120K5.76M14M34.28M28.46M
Interest Expense2.98M3.34M3.26M1.73M206K
Other Income / Expenses(2.86M)2.41M10.74M36.08M28.91M
Income Before Tax(68.48M)(114.24M)(179.21M)(173.8M)(218.81M)
Pre-Tax Margin-585.5%-789.9%-664.3%-492.7%-301.4%
Income Tax Expense(1.66M)(1.52M)1.46M(4.77M)152K
Net Income(66.82M)(112.72M)(180.66M)(169.03M)(218.96M)
Net Margin-571.2%-779.3%-669.7%-479.2%-301.7%
EPS (Basic)(2.67)(3.80)(5.08)(2.91)(3.16)
EPS (Diluted)(2.67)(3.80)(5.08)(2.90)(3.16)
Weighted Avg Shares25.06M29.66M35.59M58.21M69.28M
Weighted Avg Shares (Diluted)25.06M29.66M35.59M58.21M69.28M

Bicycle Therapeutics plc

NASDAQ:BCYC

Intrinsic Alpha fair value

Locked

Current Price

$3.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.